Uzan Gulfidan Cakmak, Borekci Sermin, Doventas Yasemin Erdogan, Koldas Macit, Gemicioglu Bilun
Haseki Training and Research Hospital, Department of Pulmonology, University of Health Sciences, Istanbul, Turkey.
Cerrahpasa Medical Faculty, Department of Pulmonary Diseases, Istanbul University-Cerrahpasa, Istanbul, Turkey.
J Asthma. 2020 Dec;57(12):1273-1279. doi: 10.1080/02770903.2019.1652644. Epub 2019 Aug 12.
: The inflammatory mechanisms underpinning asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) have not been fully elucidated. Here, we examined the levels of cysteinyl leukotrienes (cys-LTs), prostaglandin D2 (PG-D2), prostaglandin E2 (PG-E2), interleukin 5 (IL-5), and a disintegrin and metalloprotease domain (ADAM 33) in ACOS patients to determine the relationship between levels of these inflammatory markers and pulmonary functions.: Blood samples were obtained from asthma, COPD, and ACOS patients who received combined therapy and were stable for the last month to measure cys-LTs, PG-D2, PG-E2, IL-5, and ADAM33 levels. Differences between groups and their correlations with pulmonary function tests were evaluated.: In total, 24 ACOS, 27 asthma, and 35 COPD patients were included. . PG-D2 levels were higher in ACOS (120.9 ± 117.2 ng/L) and asthma (119.6 ± 111.7 ng/L) patients than in COPD (82.6 ± 46.7 ng/L) patients (p = 0.036 and p = 0.038, respectively). In ACOS patients, PG-D2, cys-LTs, and ADAM33 levels were negatively correlated with FEV1/FVC% values ( = 0.021, = 0.008, and = 0.028, respectively). In COPD patients, a negative correlation was detected between PG-E2 and FEV1/FVC% ( = 0.007), whereas positive correlations were detected between IL-5 and pulmonary function tests, including FVC, FVC%, FEV1, FEV1%, FEF25-75, and FEF25-75% ( = 0.047, = 0.005, = 0.002, = 0.002, = 0.010, and = 0.005, respectively). In asthma patients, cys-LTs levels were negatively correlated with FEV1 and FEF25-75 values ( = 0.045 and = 0.037, respectively).: PG-D2 levels may be a valuable biomarker to differentiate COPD in asthma and ACOS patients.
哮喘-慢性阻塞性肺疾病（COPD）重叠综合征（ACOS）的炎症机制尚未完全阐明。在此，我们检测了ACOS患者中半胱氨酰白三烯（cys-LTs）、前列腺素D2（PG-D2）、前列腺素E2（PG-E2）、白细胞介素5（IL-5）以及解整合素和金属蛋白酶结构域（ADAM 33）的水平，以确定这些炎症标志物水平与肺功能之间的关系。：从接受联合治疗且在过去一个月病情稳定的哮喘、COPD和ACOS患者中采集血样，以检测cys-LTs、PG-D2、PG-E2、IL-5和ADAM33水平。评估了组间差异及其与肺功能测试的相关性。：总共纳入了24例ACOS患者、27例哮喘患者和35例COPD患者。. ACOS患者（120.9±117.2 ng/L）和哮喘患者（119.6±111.7 ng/L）的PG-D2水平高于COPD患者（82.6±46.7 ng/L）（p分别为0.036和0.038）。在ACOS患者中，PG-D2、cys-LTs和ADAM33水平与FEV1/FVC%值呈负相关（分别为r = 0.021、r = 0.008和r = 0.028）。在COPD患者中，检测到PG-E2与FEV1/FVC%之间呈负相关（r = 0.007），而IL-5与包括FVC、FVC%、FEV1、FEV1%、FEF25-75和FEF25-75%在内的肺功能测试呈正相关（分别为r = 0.047、r = 0.005、r = 0.002、r = 0.002、r = 0.010和r = 0.005）。在哮喘患者中，cys-LTs水平与FEV1和FEF25-75值呈负相关（分别为r = 0.045和r = 0.037）。：PG-D2水平可能是区分哮喘和ACOS患者中COPD的有价值的生物标志物。
